Skip to main content

Table 3 Patients with CMV disease

From: A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation

UPN

ASSAY

DAYS FROM TRANSPLANT

  

-7

0

+7

+14

+21

+28

+35

+42

+49

+56

+63

+70

+77

+84

+91

+100

0133.1

Pp65 Ag

- •

- •

- •

ND

- •

- •

- •

- •

- •

-** •

-

-

-

-

-

2

 

Plasma PCR

- •

- •

- •

ND

- •

- •

- •

- •

- •

-** •

-

-

-

-

-

-

0136.1

pp65 Ag

- •

- •

- •

- •

- •

- •

- •

- •

400** •

83

1

5

2

-

4

-

 

Plasma PCR

- •

- •

- •

- •

- •

- •

- •

- •

22600** •

12300

8810

6000

1290

-

-

-

0138.1

pp65 Ag

- •

- •

- •

7•

-**

-

-

- •

60- •

23

4

-

-

-

-

19

 

Plasma PCR

- •

- •

- •

- •

-**

-

-

- •-

1230- •

4070

16700

2240

-

-

758

2250

  1. UPN: unique patient number; Ag: antigenemia; PCR: polymerase chain reaction; ND: not done; NE: not evaluate; -: negative result; **: CMV disease. Dots represent samples of patients not on pre-emptive therapy.
  2. All patients developed intestinal CMV disease and UPN 0136.1 died on day + 111 for CMV disease associated with aGVHD.